China Doxorubicin Market Research Report 2021-2025 – ResearchAndMarkets.com

0

DUBLIN–(BUSINESS WIRE)–The “China Doxorubicin Market Survey Report 2021-2025” report has been added to from ResearchAndMarkets.com offer.

According to the market research, the sales value of doxorubicin in the Chinese market increased year by year from 2016 to 2020. In particular, the sales of doxorubicin in the Chinese market reached 855 million yuan in 2019, a year-over-year increase of 69.75%.

In 2020, due to the impact of COVID-19 on the entire diagnostic and treatment departments of Chinese hospitals, the growth rate of Doxorubicin sales value in the Chinese market decreased, but the sales increased still reached about CNY 1 billion in 2020. The CAGR of sales value of Doxorubicin in Chinese market is 38.60% from 2016 to 2020.

Doxorubicin belongs to the class of anthracycline antibiotics (anthracyclines), which can inhibit RNA and DNA synthesis. It has a strong inhibitory effect on RNA and has a broad antitumor spectrum. It has an effect on a variety of tumors. Doxorubicin was developed by Alza Corporation of the United States.

According to the market research, at the end of 2020, the original drug Doxorubicin was not listed in China, but many companies got approval for generic drug listing in China and were included in the category Has Chinese national medical insurance. catalog. In 2020, there were 8 manufacturers in the Chinese doxorubicin market, including CSPC Ouyi Pharmaceutical Co., Ltd. was the main manufacturer.

The analyst expects that with the increase in the number of cancer patients in 2021-2025, the sales volume of doxorubicin in the Chinese market will increase steadily. Injection of doxorubicin liposomes has the advantages of targeting, sustained release and reduced toxicity.

Based on these advantages, the sales volume and sales of Doxorubicin Liposome Injection will continue to increase. In addition, the easing of the COVID-19 outbreak will also lead to a resumption of Doxorubicin sales growth.

Topics Covered:

  • The impact of COVID-19 on the Chinese doxorubicin market

  • China Doxorubicin Sales Value 2016-2020

  • Competitive Landscape of China Doxorubicin Market

  • Doxorubicin price in China

  • China Doxorubicin Price by Regions and Manufacturers

  • Analysis of factors affecting the development of the Chinese doxorubicin market

  • China Doxorubicin Market Outlook from 2021 to 2025

Main topics covered:

1 Relevant concepts of doxorubicin

1.1 Indications for doxorubicin

1.2 Doxorubicin Development in China

1.3 Government Approval of Doxorubicin in China

1.4 The impact of COVID-19 on Doxorubicin Sales in China

2 China Doxorubicin Sales, 2016-2020

2.1 Doxorubicin Sales Value

2.1.1 Overall sales value

2.1.2 Sales Value by Region

2.2 Doxorubicin Sales Volume

2.2.1 Overall Sales Volume

2.2.2 Sales Volume by Region

2.3 China Doxorubicin Sales by Dosage Form, 2016-2020

2.3.1 Injection

2.3.2 Injection of liposomes

3 Analysis of Doxorubicin Key Manufacturers in China, 2016-2020

3.1 Doxorubicin Key Manufacturers Market Share Analysis

3.1.1 Market Share Survey by Sales Value

3.1.2 Market Share Survey by Sales Volume

3.2 CSPC Ouyi Pharmaceutical Co., Ltd.

3.2.1 Company Profile

3.2.2 China Duomeisu (CSPC Ouyi Pharmaceutical Co., Ltd. Doxorubicin) Sales

3.3 Shanghai Fudan-zhangjiang Bio-pharmaceutical Co., Ltd.

3.3.1 Company Profile

3.3.2 China Libaoduo (Shanghai Fudan-zhangjiang Bio-pharmaceutical Co.,Ltd.) Sales

3.4 Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd.

3.4.1 Company Profile

3.4.2 China Lixing (Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd. Doxorubicin) Sales

3.5 Shenzhen Main Luck Pharmaceuticals Inc.

3.5.1 Business Profile

3.5.2 Shenzhen Main Luck Pharmaceuticals Inc. Doxorubicin Sales in China

3.6 Shanxi Powerdone Pharmaceuticals Co., Ltd.

3.6.1 Company Profile

3.6.2 Shanxi Powerdone Pharmaceuticals Co., Ltd. Doxorubicin Sales in China

4 Doxorubicin Price for Different Manufacturers in China, 2020-2021

4.1 CSPC Ouyi Pharmaceutical Co., Ltd. (Duomeisu)

4.2 Shanghai Fudan-zhangjiang Bio-pharmaceutical Co., Ltd. (Libaoduo)

4.3 Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd. (Lixing)

4.4 Shenzhen Main Lucky Pharmaceuticals Inc.

4.5 Shanxi Powerdone Pharmaceuticals Co., Ltd.

5 China Doxorubicin Market Outlook, 2021-2025

5.1 Factors Influencing the Development of China Doxorubicin Market

5.1.1 The impact of COVID-19 on the China Doxorubicin Market

5.1.2 Market Drivers and Opportunities

5.1.3 Market Threats and Challenges

5.2 Market Size Forecast

5.3 Market Trend Forecast

For more information on this report, visit https://www.researchandmarkets.com/r/pv03mm

Share.

Comments are closed.